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In this Phase 2b study, 331 low-to-moderate risk
de novo kidney transplant patients (approximately
60% deceased donors) were randomized to a more
intensive (MI) or less intensive (LI) regimen of tofac-
itinib (CP-690, 550), an oral Janus kinase inhibitor or
cyclosporine (CsA). All patients received basiliximab
induction, mycophenolic acid and corticosteroids. Pri-
mary endpoints were: incidence of biopsy-proven
acute rejection (BPAR)with a serum creatinine increase
of ≥0.3 mg/dL and ≥20% (clinical BPAR) at Month
6 and measured GFR at Month 12. Similar 6-month
incidences of clinical BPAR (11%, 7% and 9%) were
observed for MI, LI and CsA. Measured GFRs were
higher (p < 0.01) at Month 12 for MI and LI versus
CsA (65 mL/min, 65 mL/min vs. 54 mL/min). Fewer
(p < 0.05) patients in MI or LI developed chronic al-
lograft nephropathy at Month 12 compared with CsA
(25%, 24% vs. 48%). Serious infections developed in
45%, 37% and 25%of patients inMI, LI and CsA, respec-
tively. Anemia, neutropenia and posttransplant lym-
phoproliferative disorder occurred more frequently in
MI and LI compared with CsA. Tofacitinib was equiv-
alent to CsA in preventing acute rejection, was asso-
ciated with improved renal function and less chronic
allograft histological injury, but had side-effects at the
doses evaluated.
Key words: cyclosporine, kidney, renal function,
tofacitinib
Abbreviations: AUC0–12, 0–12-h area under the plasma
concentration–time curve; BID, twice daily; BPAR,
biopsy-proven acute rejection; CAN, chronic allograft
nephropathy; cg, allograft glomerulopathy; CMV, cy-
tomegalovirus; CNI, calcineurin inhibitor; CsA, cy-
closporine; cv, vascular fibrous intimal thickening;
DGF, delayed graft function; EBV, Epstein-Barr virus;
IF, interstitial fibrosis; IFG, impaired fasting glycemia;
JAK, Janus kinase; K-M, Kaplan-Meier; LI, less inten-
sive tofacitinib; LOCF, last observation carried forward;
M, Months; MDRD, Modification of Diet in Renal Dis-
ease; MI, more intensive tofacitinib; MMF, mycophe-
nolate mofetil; MPA, mycophenolic acid; NK, natural
killer; NODAT, new-onset diabetes after transplanta-
tion; PRA, panel-reactive antibody; PTLD, posttrans-
plant lymphoproliferative disorder; TA, tubular atro-
phy; TWC2, time-weighted average concentrations at
2 h postdose during the first 6 months.
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Introduction
The incidence of acute rejection in kidney transplant pa-
tients has fallen progressively without a proportionate
increase in long-term allograft survival (1). Calcineurin
inhibition remains the cornerstone of posttransplant im-
munosuppressive protocols. Long-term use of calcineurin
inhibitors (CNIs) has been associated with chronic nephro-
toxicity (2), prompting interest in CNI-free regimens. How-
ever, CNI-free protocols have been hampered by unac-
ceptably high rates of acute rejection (3–5) and other side
effects (6).
Tofacitinib (CP-690,550) is an oral Janus kinase (JAK) in-
hibitor that suppresses intracellular signal transduction of
multiple cytokines, including IL-2, IL-4, IL-7, IL-9, IL-15 and
IL-21, which are essential for homeostasis and function of
T cells, B cells and natural killer (NK) cells. A small pilot
study with tofacitinib showed promise in preventing acute
rejection in kidney allografts (7). The current study was
conducted to evaluate the efficacy and safety of tofacitinib
when combined with basiliximab induction, mycophenolic
2446
Tofacitinib in Kidney Transplant Patients
acid (MPA) and corticosteroids in de novo kidney transplant
patients.
Methods
Patients
Patients were immunologically low-to-moderate-risk recipients of primary
kidney allografts from deceased donors or HLA-mismatched living donors.
Key exclusion criteria were current panel-reactive antibody (PRA) >30%
or peak PRA >50%, positive B cell crossmatch, or pretransplant donor-
specific anti-HLA antibodies. Allografts from extended-criteria donors and
cardiac-death donors were excluded.
Study design
This was a randomized, multicenter, Phase 2b study (ClinicalTrials.gov iden-
tifier NCT00483756) conducted in 57 centers in 15 countries. The trial was
approved by the Institutional Review Boards and/or Independent Ethics
Committees at each of the investigational centers participating in the study
or a central IRB. It was conducted in compliance with the Declaration of
Helsinki and the International Conference on Harmonisation Good Clinical
Practice Guidelines. All patients provided written informed consent.
Following kidney transplantation, patients were randomized 1:1:1 to one
of two tofacitinib regimens or cyclosporine (CsA) microemulsion (Novartis,
Basel, Switzerland). A computer generated randomization schedule was
used to assign patients to treatment groups and randomization was strat-
ified with respect to donor source. In the more intensive (MI) tofacitinib
group, patients received tofacitinib 15 mg twice daily (BID) in Months 1–6,
then 10 mg BID in Months 7–12. In the less intensive (LI) tofacitinib group,
patients received tofacitinib 15 mg BID in Months 1–3, then 10 mg BID in
Months 4–12. Patients and investigators were blinded to the assignment
to MI versus LI but were aware of assignment to tofacitinib versus CsA.
In the control group, CsA was started at 8–10 mg/kg/day and adjusted to
achieve 12-h trough whole blood levels of 125–400 ng/mL in Months 1–3
and 100–300 ng/mL in Months 4–12.
All patients received basiliximab induction (20 mg intravenously on Days 0
and 4), MPA products at an initial dose of 2 g/day mycophenolate mofetil
(MMF), or 1.44 g/day enteric-coated MPA, and corticosteroids through
at least Month 12. Cytomegalovirus (CMV) prophylaxis was required for
3months in CMV-seronegative recipients of kidneys fromCMV-seropositive
donors, while other donor–recipient CMV combinations received prophy-
laxis according to local practice. GFR was measured at Months 6 and 12 by
determining iohexol serum clearance. Protocol biopsies of the allograft were
required at the time of implantation and Month 12. Patients underwent pe-
riodic monitoring of Epstein–Barr virus (EBV) load in whole blood and BK
virus load in plasma according to the protocol. Patients who completed 12
months of treatment were eligible for a long-term extension study.
Blinding
The investigator and patient were aware of the treatment assignment if
the patient was randomized to the control arm (CsA) but were blinded to
assignment to MI versus LI if the patient was randomized to tofacitinib.
Patients in the tofacitinib arms received the same dose during the first
3 months (15 mg BID) and after Month 6 (10 mg BID); therefore, the
blinding period was limited to Months 4–6, during which time patients in
the MI group received 15 mg BID and patients in the LI group received 10
mg BID. DuringMonths 4–6, each patient randomized to tofacitinib received
three bottles of identical appearance containing tofacitinib 5 mg tablets or
matching placebo. The patient was instructed to take one tablet from each
bottle in the morning and in the evening.
Efficacy and safety endpoints
The primary efficacy endpoint was the incidence of first clinical biopsy-
proven acute rejection (“clinical BPAR”) at Month 6. To meet this endpoint,
the patient must have had BPAR and an increase in serum creatinine of
≥0.3 mg/dL and ≥20% from the prerejection baseline. The other primary
endpoint wasmeasured GFR atMonth 12. Allograft biopsies were reviewed
by a central pathologist. A separate secondary endpoint of “total BPAR”
was also analyzed based on the central pathologist’s finding of acute/active
cellular rejection or antibody-mediated rejection according to the Banff 2003
classification (8), regardless of clinical evidence of changes in renal func-
tion. All for-cause, surveillance, and protocol biopsies were included in the
assessment for total BPAR.
Secondary endpoints included total BPAR rate at Months 6 and 12, esti-
mated GFR at Month 12 calculated from the Modification of Diet in Renal
Disease (MDRD) (9) and Nankivell (10) equations, chronic allograft lesions
at Month 12, and adverse events. New-onset diabetes after transplantation
(NODAT) was defined as the need for treatment of hyperglycemia for ≥30
consecutive days or fasting serum glucose ≥126 mg/dL. Impaired fasting
glycemia was defined as fasting serum glucose 110–125 mg/dL. Stage-1
hypertension was defined as systolic blood pressure 140–159 mmHg or
diastolic blood pressure 90–99 mmHg.
Drug exposure and exposure-response analyses
The 0–12-h area under the plasma concentration–time curve (AUC0–12) of
MPA at steady state was ascertained using population pharmacokinetics
from 2476 MPA concentrations from 276 patients who received tofacitinib
or CsA.
Prespecified exploratory exposure-response analyses were performed to
evaluate the relationship between tofacitinib exposure and clinical events.
Individual tofacitinib exposure was measured as time-weighted average
concentrations at 2 h postdose (TWC2). TWC2 was calculated by dose nor-
malizing and averaging individual 2-h concentrations over the first 6 months,
and recalculating the 2-h concentration for the assigned dose (10 or 15 mg
BID) through Month 6.
Statistical analyses
All efficacy and safety analyses were based on the full analysis set, defined
as patients who received at least one dose of study treatment. Primary
analyses were performed to evaluate both noninferiority in the 6-month inci-
dence of clinical BPAR and superiority in 12-month measured GFR between
MI or LI and the CsA control group. The Hochberg multiple comparison pro-
cedure was used to test each tofacitinib group versus CsA, and a step-down
procedure was used for evaluating the two primary endpoints (clinical BPAR
before measured GFR) at the overall one-sided type-I error level of 20%. To
meet the noninferiority criterion for 6-month clinical BPAR incidence, the
upper one-sided 80% confidence limit of the difference (tofacitinib–CsA)
had to be <12%. The noninferiority margin of 12% was chosen based on a
literature review of the treatment effect of the CNIs and was applied to both
clinical BPAR and total BPAR evaluations. A sample size of 100 patients per
group would provide 81% power to declare noninferiority in the 6-month
clinical BPAR rate and superiority in the 12-month measured GFR jointly
between at least one of the tofacitinib groups and CsA.
Clinical BPAR and total BPAR data were evaluated using the Kaplan–Meier
survival method. Measured GFR at Month 12 and estimated GFR were
analyzed using a linear mixed-effects model for repeated measures as the
primary analysis, with sensitivity analyses performed using last observation
carried forward (LOCF) and imputation of graft loss or death as zero, where
applicable.
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Figure 1: Patient disposition.
Results
Patient disposition and demographics
In total, 331 patients were randomized and 322 patients
received study treatment (106 in MI, 107 in LI and 109 in
CsA; Figure 1). These patients were randomized from 13
February 2008 to 27 February 2009. Baseline characteris-
tics were similar among the treatment groups (Table 1).
More patients discontinued MI and LI than CsA prior to
Month 12 (43.4% vs. 44.9% vs. 28.4%, respectively). A
similar proportion of patients in each group discontinued
due to lack of efficacy, but more patients in MI and LI
discontinued because of infection or hematological abnor-
malities (Figure 1).
Acute rejection
The primary efficacy endpoint of 6-month incidence of clin-
ical BPAR met noninferiority criterion for both MI and LI
when compared with CsA (11.4% and 7.1% vs. 9.0%; Ta-
ble 2; Figure 2, panel A). Similarly, the 6- and 12-month
incidences of total BPAR for MI and LI were noninferior
to CsA (Table 2; Figure 2, panel C). No clinically meaning-
ful difference was observed between either MI or LI and
CsA in the 12-month incidence of total BPAR in deceased
donors or living donors, or severe cellular rejections (grade
IIB or III). Antibody-mediated rejection of grade II or higher
was observed in the CsA group only. Locally diagnosed
and treated acute rejection was not more frequent in MI
or LI compared with the CsA group. More black patients
developed acute rejection while receiving tofacitinib com-
pared with CsA but the difference did not reach statistical
significance.
Renal function
The co-primary endpoint of measured GFR was signifi-
cantly higher (p < 0.01) at Month 12 in MI and LI than
CsA (64.6 mL/min vs. 64.7 mL/min vs. 53.9 mL/min, re-
spectively; Table 3; Figure 2, panel B). This was also ob-
served at Month 6. Similarly, estimated GFR values for MI
and LI calculated from the MDRD and Nankivell equations
were significantly higher than CsA at Months 6 and 12.
Sensitivity analyses of estimated GFR based on LOCF and
imputation of graft loss or death as zero supported these
results. The higher estimated GFR values inMI and LI were
observed as early as 1 month posttransplant and persisted
through Month 12 (Figure 2, panel D).
Chronic allograft damage
AtMonth 12, significantly fewer (p< 0.05) patients inMI or
LI developed chronic allograft nephropathy (CAN) according
to the Banff 2003 criteria compared with CsA (Table 3). In
particular, fewer patients in MI or LI developed grade-II
or grade-III CAN. When Month 12 protocol biopsies were
compared with implantation biopsies, fewer patients in MI
or LI showed progression (increase in CAN grade or Banff
chronicity score).With regard to the individual Banff chronic
lesion scores, a significantly lower proportion of patients
showed an increase in ci (interstitial fibrosis [IF]) and/or
ct (tubular atrophy [TA]) scores in the tofacitinib groups
(Table 3).
Patient and allograft survival
No statistically significant difference in patient survival was
observed between either MI or LI and CsA (96.4% [MI]
and 96.6% [LI] vs. 96.9% [CsA]; Table 2). Infection was
implicated as the cause of death in six of eight patients.
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Table 1: Baseline characteristics, demography and concomitant immunosuppressant dosage
MI (N = 106) LI (N = 107) CsA (N = 109)
Recipient
Age, years, mean (SD) 47.8 (12.1) 45.8 (12.6) 47.1 (12.9)
Male, n (%) 82 (77.4) 80 (74.8) 70 (64.2)
Race
White, n (%) 66 (62.3) 71 (66.4) 78 (71.6)
Black, n (%) 16 (15.1) 21 (19.6) 12 (11.0)
Other, n (%) 24 (22.6) 15 (14.0) 19 (17.4)
HLA-mismatch, mean (SD)
Deceased donors 3.1 (1.9) 3.1 (2.0) 3.4 (1.7)
Living donors 3.9 (1.5) 3.9 (1.4) 3.6 (1.3)
CMV D+R-, n (%) 17 (16.0) 16 (15.0) 10 (9.2)
Negative recipient EBV serostatus, n (%) 7 (6.6) 6 (5.6) 9 (8.3)
Diabetic pretransplant, n (%) 21 (19.8) 25 (23.4) 25 (22.9)
On dialysis pretransplant, n (%) 100 (94.3) 99 (92.5) 99 (90.8)
Donor
Deceased, n (%) 65 (61.3) 65 (60.7) 67 (61.5)
Black, n (%) 8 (7.5) 11 (10.3) 5 (4.6)
Age, years, mean (SD) 42 (13) 42 (15) 40 (13)
Cold ischemic time (hours for deceased donors),
median (interquartile range)
16.0 (9.3–20.0) 16.0 (10.0–21.4) 16.1 (11.6–20.0)
Concomitant immunosuppressant dosage (median)
MMF dose (g/day) at Month 6 1.5 2.0 2.0
MMF dose (g/day) at Month 12 1.5 1.5 2.0
Prednisone dose (mg/day) at Month 12 5 5 5
CMV = cytomegalovirus; CsA = cyclosporine; EBV = Epstein-Barr virus; LI = less intensive tofacitinib; MI = more intensive tofacitinib;
MMF = mycophenolate mofetil; PRA = panel-reactive antibody; SD = standard deviation.
Among surviving patients, graft failure occurred in two,
five and one patients in the MI, LI and CsA groups, re-
spectively. In the LI group, technical complications (surgical
complications or renal artery/vein thrombosis) accounted
for three of five cases of graft failure. In another LI pa-
tient who discontinued tofacitinib after one day, graft failure
occurred due to acute rejection approximately 9 months
posttransplant.
Safety and tolerability
Adverse events occurring in >10% of patients in any treat-
ment group, and adverse events of special interest, are
shown in Table 4. Serious infections and CMV disease
(Figure 2, panel E) occurred more frequently in MI and
LI than in the CsA group. Fewer patients in MI or LI de-
veloped NODAT or impaired fasting glycemia (24.2% [MI]
and 17.8% [LI] vs. 38.2% [CsA]).
Malignancy developed in six patients in MI, one patient in
LI and one patient in CsA. The six patients in MI included
three cases of solid malignancy likely to have been preex-
isting at the time of transplantation (one case each of renal
cell carcinoma and prostate cancer that occurred within
3 months posttransplant, and one case of prostate cancer
in a patient with elevated prostate surface antigen level at
the time of transplantation). Posttransplant lymphoprolifer-
ative disorder (PTLD) developed in two patients in MI and
one patient in LI. After Month 12, two additional patients
in the MI group developed PTLD. Among the five patients
who developed PTLD, four were EBV seropositive at the
time of transplantation.
More patients had hemoglobin levels<8 or<10 g/dL in MI
and LI, and more patients had absolute neutrophil counts
<500 or <1000 cells/lL in MI than in the CsA group
(Table 4). Mean cell counts of CD3+ T cells and CD56+
NK cells were lower in MI and LI than CsA at Months 6
and 12 (Table 4).
At Month 12, total serum and LDL cholesterol levels were
slightly higher in LI than in the CsA group, without a differ-
ence in the LDL/HDL ratio. However, lipid-lowering agents
were used less frequently in the LI group. In MI and LI,
fewer patients had ≥stage-1 hypertension at Month 6, and
fewer patients used >2 antihypertensive medications at
Months 6 and 12.
Pharmacokinetics and exposure-response analysis
Through Month 6, model-predicted MPA AUC0–12 was
37.4% higher (90% confidence interval: 25.4, 50.6%) in
the tofacitinib groups compared with the CsA group. Ge-
ometric mean (90% confidence interval) model-predicted
MPA AUC0–12 for MMF 1 g BID for the CsA group was
42.8 (39.0, 46.9) mg h/L. Exposure-response analysis
indicated that at tofacitinib TWC2 below the median
(125 ng/mL), the 12-month incidences of total BPAR, se-
rious infections, and CMV disease were comparable to
those in the CsA group (Figure 2, panel F), whereas higher
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Table 2: Efficacy, death and graft loss
MI (N = 106) LI (N = 107) CsA (N = 109)
Efficacy Month 6 Month 12 Month 6 Month 12 Month 6 Month 12
Patients with first clinical
BPAR, n (%)1
11 (11.4) 11 (11.4) 7 (7.1) 7 (7.1) 9 (9.0) 9 (9.0)
Difference (60% CI) 2.5 (−1.2, 6.1) 2.5 (−1.2, 6.1) −1.8 (−5.1, 1.5) −1.8 (−5.1, 1.5) − −
Difference (95% CI) 2.5 (−6.0, 11.0) 2.5 (−6.0, 11.0) −1.8 (−9.4, 5.8) −1.8 (−9.4, 5.8) − −
Patients with first total
BPAR, n (%)1
16 (16.1) 17 (17.4) 12 (12.4) 14 (15.4) 18 (17.7) 19 (18.8)
Difference (60% CI) −1.7 (−6.2, 2.8) −1.4 (−6.1, 3.2) −5.4 (−9.6, −1.1) −3.4 (−8.0, 1.3) − −
Difference (95% CI) −1.7 (−12.1, 8.7) −1.4 (−12.2, 9.3) −5.4 (−15.3, 4.6) −3.4 (−14.2, 7.4) − −
Month 12 Month 12 Month 12
Total BPAR in deceased donor recipients, n (%)1 7 (11.8) 8 (13.9) 10 (16.4)
Total BPAR in living donor recipients, n (%)1 10 (25.7) 6 (18.0) 9 (22.3)
Total BPAR in black patients, n (%)1 4 (30.2) 4 (29.5) 1 (8.3)
Total BPAR: acute/active cellular rejection, n (%) 16 (15.1) 13 (12.1) 18 (16.5)
Grade IA 2 (1.9) 0 1 (0.9)
Grade IB 3 (2.8) 0 4 (3.7)
Grade IIA 7 (6.6) 11 (10.3) 8 (7.3)
Grade IIB 3 (2.8) 2 (1.9) 5 (4.6)
Grade III 1 (0.9) 0 0
Total BPAR: antibody-mediated rejection, n (%) 2 (1.9) 1 (0.9) 5 (4.6)
Grade I 2 (1.9) 1 (0.9) 1 (0.9)
Grade II 0 0 4 (3.7)
Grade III 0 0 0
Patients with locally diagnosed and treated acute clinical
rejection (adverse event), n (%)1
26 (26.9) 18 (18.7) 25 (24.8)
Black patients, n (%)1 4 (28.2) 5 (27.0) 2 (16.7)
Repeat rejection, n (%)1 0 1 (1.5) 4 (4.5)
Death Month 12 Month 12 Month 12
Patient survival at Month 12,%1 96.4 96.6 96.9
Deaths within 12 months, n 3 2 3
Cause of death • Pneumonia, sepsis
• Rhabdomyolysis, brain
edema
• Bronchopulmonary
aspergillosis, brain
infarction, aspiration
pneumonia
• Cardiac arrest
(electromechanical
dissociation)
• Bronchopulmonary
aspergillosis
• Sepsis, brain infarction
• Pneumonia
• Peritonitis, sepsis
Graft loss Month 12 Month 12 Month 12
Graft survival (death-censored) at Month 12,%1 98.0 94.2 99.1
Graft loss (excluding death) at Month 12, n 2 5 1
Cause of graft loss
Acute rejection - 2 -
Primary nonfunction 1 - -
Surgical complication - 1 -
Thrombosis 1 2 1
BPAR = biopsy-proven acute rejection; CI = confidence interval; CsA = cyclosporine; LI = less intensive tofacitinib; MI = more intensive tofacitinib.
n = number of patients with condition.
1Kaplan–Meier estimates.
tofacitinib exposure was associated with evidence of over-
immunosuppression or was associated with more infec-
tions and CMV. All five PTLD cases were associated with
above-median tofacitinib TWC2s.
Discussion
The primary objectives of this study were to demonstrate
noninferiority of tofacitinib over CsA in preventing acute
rejection, and superiority of tofacitinib with respect to renal
function. The rates of clinical BPAR and total BPAR in the
three treatment arms fulfilled the prespecified criterion for
noninferiority. The upper bounds of the 95% confidence
intervals of the difference between MI or LI and CsA were
also <12% (Table 2). The total BPAR rate in the CsA group
(17.7% [Month 6] and 18.8% [Month 12]) was consistent
with the range reported in the literature (11,12). Sub-group
analyses did not reveal a higher rate of severe acute cellular
rejection or humoral rejection in the tofacitinib groups.
The co-primary endpoint of measured GFR at Month 12
was significantly higher in both MI and LI compared
with CsA (64.6 [MI] and 64.7 [LI] vs. 53.9 [CsA] mL/min)
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Figure 2: (Panel A) K-M survival curves for clinical BPAR. (Panel B) Least squares means of measured GFR at Months 6 and 12.
(Panel C) K-M survival curves for total BPAR. (Panel D) Least squares means of estimated GFR calculated by the MDRD equation versus
time. (Panel E) K-M survival curves for CMV disease through Month 12. (Panel F) Exposure-response analyses indicated that at tofacitinib
exposure below the median, the 12-month incidences of CMV disease and serious infection were comparable to those in the CsA group.
(Table 3). As GFR in CNI-treated kidney transplant patients
typically declines by 1–2 mL/min/year (13), the observed
difference of approximately 10 mL/min between the to-
facitinib groups and CsA is of clinical relevance. One-year
renal function has been correlated with graft survival (14),
and improved renal function in the tofacitinib groups at
Month 12 may prove advantageous for long-term graft
outcome.
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Table 3: Renal function and allograft histology
MI (N = 106) LI (N = 107) CsA (N = 109)
Renal function Month 6 Month 12 Month 6 Month 12 Month 6 Month 12
Measured GFR, mL/min, LSM 67.4 64.6 73.6 64.7 57.2 53.9
(SE) (2.6) (2.7) (2.5) (2.6) (2.3) (2.4)
Difference (mL/min) 10.2∗∗ 10.6∗∗ 16.4∗∗∗∗ 10.8∗∗ − −
Estimated GFR (MDRD), 62.9 66.9 65.4 66.8 55.2 55.0
mL/min/1.73 m2, LSM (SE) (2.0) (2.1) (2.1) (2.1) (1.9) (1.9)
Difference, mL/min/1.73 m2 7.7∗∗ 12.0∗∗∗∗ 10.2∗∗∗ 11.8∗∗∗∗ − −
Estimated GFR (MDRD, 61.8 64.3 64.0 64.6 54.2 53.9
LOCF), mL/min/1.73 m2,
LSM (SE)
(2.0)∗∗ (2.0)∗∗∗ (2.0)∗∗∗ (2.0)∗∗∗ (1.9) (1.9)
Estimated GFR (Nankivell, 73.2 75.6 74.5 75.4 66.8 66.9
LOCF), mL/min, LSM (SE) (1.9)∗ (1.9)∗∗ (1.9)∗∗ (1.9)∗∗ (1.8) (1.8)
Estimated GFR (Nankivell, 70.3 72.6 71.1 71.5 64.7(2.3) 64.8
LOCF + imputed), mL/min,
LSM (SE)
(2.4) (2.4)∗ (2.4) (2.4)∗ (2.3)
Estimated GFR in deceased 74.1 78.1 75.7 77.6 67.7 67.8
donor recipients (Nankivell,
LOCF), mL/min, LSM (SE)
(1.9)∗ (2.0)∗∗∗ (2.0)∗∗ (2.0)∗∗∗ (1.8) (1.9)
Serum creatinine, mg/dL, 1.32 1.20 1.26 1.21 1.42 1.44
mean (SD) (0.37) (0.29) (0.39) (0.31) (0.43) (0.44)
Patients with DGF, n (%) 13 (12.3) 10 (9.4) 9 (8.3)
DGF in deceased donor
recipients, n (%)
11 (14.5) 6 (8.6) 8 (11.1)
Patients with proteinuria
>500 mg/day, n (%) 6 (9.2) 5 (8.6) 4 (6.0) 4 (7.0) 5 (6.3) 3(4.1)
>1500 mg/day, n (%) 0 1 (1.7) 0 0 1 (1.3) 0
Allograft histology Month 12 Month 12 Month 12
Patients with CAN1 13/52 (25.0)∗∗ 11/46 (23.9)∗ 28/58 (48.3)
n/N’ (%)
Grade I 10 (19.2) 6 (13.0) 15 (25.9)
Grade II 2 (3.9) 4 (8.7) 7 (12.1)
Grade III 1 (1.9) 1 (2.2) 6 (10.3)
p-value of difference in overall distribution 0.0059 0.0111 −
Patients with increase in CAN1 grades, n/N (%) 13/49 (26.5) 10/44 (22.7)∗ 23/51 (45.1)
Patients with increase in Banff chronicity score, n/N (%) 18/46 (39.1)∗ 19/43 (44.2) 29/48 (60.4)
Patients with increase in Banff chronic lesions scores, n/N (%)
Increase in cg 0/46 (0) 0/43 (0) 0/48 (0)
Increase in ci 12/46 (26.1)∗ 10/43 (23.3)∗ 22/48 (45.8)
Increase in ct 13/46 (28.3) 10/43 (23.3)∗ 22/48 (45.8)
Increase in cv 11/46 (23.9) 11/41 (26.8) 16/47 (34.0)
Notes: LSM (SE) is based on random effects linear model for repeated measures. n, number of patients with condition. N, number of
patients with both implantation and Month 12 biopsies. N’, number of patients with Month 12 biopsy.
1According to Banff 2003 criteria.
p-value versus CsA: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001; nominal p-values ≥ 0.05 are considered not statistically
significant.
CAN = chronic allograft nephropathy; cg = allograft glomerulopathy; ci = interstitial fibrosis; CsA = cyclosporine; ct = tubular atrophy;
cv = vascular fibrous intimal thickening; DGF = delayed graft function; GFR = glomerular filtration rate; LI = less intensive tofacitinib;
LOCF = last observation carried forward; LSM = least squares mean; MDRD = Modification of Diet in Renal Disease; MI = more
intensive tofacitinib; SE = standard error; SD = standard deviation.
The lower prevalence of CAN in both tofacitinib groups
was consistent with the observed improvement in GFR.
An increase in the prevalence of CAN from implantation to
Month 12 was seen in all treatment groups but less in the
tofacitinib groups. The between-group difference in pro-
gression of allograft lesions from implantation to Month 12
was driven primarily by an increase in the severity of IF and
TA, and to a lesser extent by an increase in arterial intimal
thickening in the CsA group. This may indicate a long-term
benefit from use of tofacitinib, as early tubulointerstitial
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Table 4: Safety
MI (N = 106) LI (N = 107) CsA (N = 109)
Adverse events (all causality) occurring >10% in any treatment group, n (%)
Anemia 49 (46.2) 43 (40.2) 28 (25.7)
Leukopenia 31 (29.2) 19 (17.8) 12 (11.0)
Neutropenia 14 (13.2) 6 (5.6) 2 (1.8)
Abdominal distension 6 (5.7) 8 (7.5) 11 (10.1)
Abdominal pain 18 (17.0) 5 (4.7) 16 (14.7)
Constipation 36 (34.0) 38 (35.5) 30 (27.5)
Diarrhea 28 (26.4) 29 (27.1) 22 (20.2)
Nausea 29 (27.4) 27 (25.2) 24 (22.0)
Vomiting 17 (16.0) 13 (12.1) 19 (17.4)
Fatigue 9 (8.5) 15 (14.0) 11 (10.1)
Edema 15 (14.2) 11 (10.3) 12 (11.0)
Edema peripheral 25 (23.6) 19 (17.8) 30 (27.5)
Pyrexia 21 (19.8) 17 (15.9) 14 (12.8)
Transplant rejection 22 (20.8) 13 (12.1) 23 (21.1)
BK virus infection 15 (14.2) 19 (17.8) 6 (5.5)
CMV infection 14 (13.2) 9 (8.4) 3 (2.8)
CMV viremia 29 (27.4) 19 (17.8) 12 (11.0)
Urinary tract infection 25 (23.6) 27 (25.2) 27 (24.8)
Upper respiratory tract infection 17 (16.0) 9 (8.4) 17 (15.6)
Graft complication 12 (11.3) 17 (15.9) 10 (9.2)
Incision-site pain 9 (8.5) 11 (10.3) 3 (2.8)
Procedural pain 21 (19.8) 15 (14.0) 14 (12.8)
Blood creatinine increased 17 (16.0) 20 (18.7) 20 (18.3)
Weight increased 15 (14.2) 12 (11.2) 14 (12.8)
Fluid overload 11 (10.4) 5 (4.7) 6 (5.5)
Hyperglycemia 10 (9.4) 7 (6.5) 13 (11.9)
Hyperkalemia 18 (17.0) 20 (18.7) 14 (12.8)
Hyperlipidemia 10 (9.4) 10 (9.3) 13 (11.9)
Hypocalcemia 12 (11.3) 4 (3.7) 4 (3.7)
Hypokalemia 13 (12.3) 11 (10.3) 3 (2.8)
Hypophosphatemia 14 (13.2) 10 (9.3) 13 (11.9)
Back pain 7 (6.6) 12 (11.2) 4 (3.7)
Headache 13 (12.3) 21 (19.6) 14 (12.8)
Tremor 8 (7.5) 8 (7.5) 19 (17.4)
Insomnia 6 (5.7) 10 (9.3) 13 (11.9)
Dysuria 13 (12.3) 8 (7.5) 8 (7.3)
Hematuria 16 (15.1) 11 (10.3) 11 (10.1)
Cough 16 (15.1) 7 (6.5) 7 (6.4)
Dyspnea 11 (10.4) 9 (8.4) 7 (6.4)
Acne 14 (13.2) 18 (16.8) 4 (3.7)
Rash 12 (11.3) 6 (5.6) 7 (6.4)
Hypertension 24 (22.6) 23 (21.5) 30 (27.5)
Hypotension 18 (17.0) 13 (12.1) 7 (6.4)
AEs of special interest at Month 12, n (%)
Serious infections1 37 (44.5)∗∗ 33 (37.0) 24 (25.3)
Clinically significant infection1 38 (45.2) 38 (42.8) 32 (32.8)
CMV disease (including CMV syndrome)1 16 (19.5)∗∗ 11 (13.3)∗ 4 (4.5)
BK virus nephropathy1 2 (2.6) 3 (3.9) 1 (1.1)
Malignancy 6 (5.7) 1 (0.9) 1 (0.9)
PTLD1 2 (3.1) 1 (1.6) 0
NODAT1 7 (9.9) 6 (9.3) 14 (20.8)
IFG1 10 (17.9) 6 (10.4)∗ 19 (28.6)
NODAT/IFG1 15 (24.2) 11 (17.8)∗ 26 (38.2)
damage has been shown to predict long-term graft sur-
vival (15). Early-onset IF–TA may result from unchecked al-
loimmunity, chronic antibody-mediated rejection or direct
CNI toxicity, though the relative contribution of these fac-
tors continues to be debated and will vary between indi-
viduals (16–18). Similarly, the mechanism(s) through which
tofacitinib is associatedwith less IF–TA is unknown, though
the absence of CNI is likely to be a contributing factor.
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Table 4: Continued.
Laboratory and vital signs Month 6 Month 12 Month 6 Month 12 Month 6 Month 12
Hemoglobin, g/dL, mean (SD) 12.0 (1.8) 12.9 (1.7) 12.2 (1.5) 12.9 (1.4) 12.6 (1.7) 13.0 (1.5)
Patients with hemoglobin <8
g/dL, n (%)
16 (15.2) 11 (10.6) 8 (7.4)
Patients with hemoglobin <10
g/dL, n (%)
68 (64.8) 68 (65.4) 55 (50.9)
Absolute neutrophil count,
K/mm3, mean (SD)
4.0 (2.3) 4.0 (1.9) 3.6 (2.4) 3.8 (1.7) 4.2 (1.9) 4.3 (2.2)
Patients with neutrophil
counts <500/mm3, n (%)
4 (3.8) 2 (1.9) 2 (1.9)
Patients with neutrophil
counts <1000/mm3, n (%)
19 (18.1)∗∗∗ 4 (3.8) 4 (3.7)
Total WBC count, K/mm3,
mean (SD)
5.7 (2.7) 5.7 (2.2) 5.3 (2.4) 5.7 (2.1) 6.4 (2.3) 6.7 (2.4)
Absolute lymphocyte count,
K/mm3, mean (SD)
1.1 (0.6) 1.1 (0.5) 1.2 (0.5) 1.2 (0.6) 1.6 (0.7) 1.7 (0.6)
Absolute platelet count,
K/mm3, mean (SD)
265 (107) 246 (93) 253 (91) 242 (70) 245 (61) 239 (64)
Absolute CD3+ T cell count,
cells/lL mean (SD)
812 (379) 797 (369) 970 (410) 956 (522) 1268 (693) 1353 (648)
Absolute CD56+ NK cell
count, cells/lL, mean (SD)
68 (64) 96 (101) 65 (49) 77 (58) 170 (123) 169 (123)
Total serum cholesterol,
mg/dL, LSM
201 195 204 209 200 194
Serum LDL cholesterol,
mg/dL, LSM
111 111 110 115 114 108
Serum LDL/HDL ratio, LSM 2.3 2.2 2.4 2.3 2.4 2.2
Patients who used
lipid-lowering drugs, n (%)
38 (56.7) 28 (59.6) 26 (37.7) 17 (37.8) 44 (52.4) 38 (55.9)
Patients with ≥stage-1
hypertension, n (%)
17 (25.8)∗∗∗∗ 21 (35.6) 26 (37.7) 20 (33.9) 39 (48.8) 32 (41.6)
Patients who used >2
anti-hypertensive
medications, n (%)
32 (47.8)∗∗ 24 (51.1)∗ 38 (55.1)∗ 25 (55.6) 59 (70.2) 49 (72.1)
1Kaplan–Meier estimates.
p-value versus CsA: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.
CMV = cytomegalovirus; CsA = cyclosporine; IFG = impaired fasting glycemia; LI = less intensive tofacitinib; LSM = least squares
mean; MI = more intensive tofacitinib; NODAT = new-onset diabetes after transplantation; PTLD = posttransplant lymphoproliferative
disorder; WBC = white blood cell.
The main concerns identified with the tofacitinib regi-
mens in this study were the increased rates of infection
and PTLD. Beyond Month 12, two additional patients in
the MI group developed PTLD. These findings suggest
an excessive level of immunosuppression with the regi-
mens used in the study and correlated with elevated to-
facitinib exposure. In this study, tofacitinib dose reduc-
tion was not permitted until Month 3 (LI) or Month 6
(MI). Among tofacitinib-treated patients, the incidence of
CMV disease was reduced by approximately one-third by
the use of ganciclovir/valganciclovir prophylaxis (data not
shown). Exposure-response analysis indicated that below-
median tofacitinib exposure was associated with a lower
incidence of infection while providing comparable protec-
tion from total BPAR as compared to higher tofacitinib
exposure.
The higher incidence of anemia and neutropenia in the to-
facitinib groups in the early posttransplant period may be
partly due to inhibition of JAK2, a tyrosine kinase that medi-
ates hematopoiesis. It should be noted that, due to a lack
of pharmacokinetic interaction between MPA and tofaci-
tinib, MPA exposure was higher among tofacitinib-treated
patients in the first 6 months posttransplant. A decrease
of the mean MMF dose in tofacitinib-treated patients later
posttransplant (1.5 g/day in MI and LI vs. 2.0 g/day in the
CsA group at Month 12; Table 1) would have resulted in
more comparable MPA exposure among the treatment
groups. Indeed the elevated MPA exposure in tofacitinib-
treated patients may have partly accounted for the efficacy
of the MI and LI groups, as well as some adverse events,
such as over-immunosuppression and hematological ab-
normalities. Compared with CsA, fewer patients in the to-
facitinib groups experienced NODAT or impaired fasting
glycemia, though this difference did not reach statistical
significance. If confirmed, the lower diabetogenicity of a
tofacitinib-based regimen will be important given the ad-
verse impact of NODAT on patient and graft outcome (19).
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A potential limitation of this study is the use of a CsA-based
control group. Tacrolimus is now the most frequently used
CNI in kidney transplantation, largely attributable to the
lower rates of acute rejection reported with tacrolimus.
However, very low rejection rates can now be achieved
with CsA (20), and recent studies with the microemulsion
formulation of CsA have reported similar rejection rates
compared with tacrolimus (21–24). Therefore, this study
remains relevant to clinical practice. In addition, discontinu-
ation rates were high in all three treatment groups, ranging
from 28% in the CsA group to 44–45% in the tofacitinib
groups. The discontinuation rate due to lack of efficacy
was similar in each group, suggesting that the improved
renal function in MI and LI cannot be attributed to a bias in
selecting nonrejecting patients.
The overall findings of this Phase 2b study suggest
that tofacitinib, when combined with MPA at conven-
tional doses, is effective in preventing allograft rejection
and has a beneficial effect on renal allograft function
and parenchymal preservation. However, this result was
achieved at the expense of hematological toxicity and
over-immunosuppression as demonstrated by increased
incidences of serious infection, opportunistic viral infec-
tion and PTLD. Exposure-response analyses have identi-
fied tofacitinib levels that are tentatively associated with
lower infection risk without loss of efficacy. This sug-
gests that adjustments to the tofacitinib regimens used
in this study may permit the benefits of improved GFR and
less CAN without over-immunosuppression, indicating the
need for additional concentration-controlled studies to opti-
mize tofacitinib-based immunosuppression in kidney trans-
plant patients. Overall, this study suggests that tofacitinib
has the potential to be used in a CNI-free regimen for the
prevention of renal allograft rejection.
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